Denali therapeutics announces fda has selected dnl126 (etv:sgsh) for mps iiia (sanfilippo syndrome type a) for start pilot program intended to accelerate development of rare disease therapies

South san francisco, calif., june 03, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the u.s. food and drug administration (fda) has selected dnl126 for participation in the support for clinical trials advancing rare disease therapeutics (start) pilot program. dnl126 is an investigational enzyme replacement therapy designed to cross the bbb for the potential treatment of mps iiia (sanfilippo syndrome type a).
DNLI Ratings Summary
DNLI Quant Ranking